Bacterial Conjunctivitis Market is projected to hit US$ 436.7 Mn by 2025 decreasing at a CAGR of – 0.54% from 2017 to 2025.

Bacterial Conjunctivitis Market
Bacterial Conjunctivitis Market

The latest market report published by Credence Research, Inc. “Global Bacterial Conjunctivitis Market – Growth, Future Prospects, Competitive Analysis, 2017 – 2025,” the global bacterial conjunctivitis market was valued at US$ 458.4 Mn in 2016, and is expected to reach US$ 436.7 Mn by 2025 decreasing at a CAGR of – 0.54% from 2017 to 2025.

Request Sample: https://goo.gl/YK4gxr

Browse the full report Global Bacterial Conjunctivitis Market – Growth, Future Prospects, Competitive Analysis, 2017 – 2025 report @ https://goo.gl/DV82e7

Market Insights:

Conjunctiva is a delicate lining that covers the eyelids and is part of the outer surface of the eyeball. Bacterial conjunctivitis results when the conjunctiva is inflamed by bacteria, allergies or chemical irritants. The market is highly dynamic as currently very few investigative studies are being conducted with a weak product pipeline, owing to drug expiry issues, generic version of the antibiotics are going to dominate the market throughout the forecast period 2017-2025.

In 2016, fluoroquinolones segment held the largest market share chiefly due to factors such as the broad spectrum antimicrobial activity offered by fluoroquinolones against the Gram-positive, Gram-negative and anaerobic organism. The limitations of this segment throughout the forecast period are the forthcoming patent expiration of blockbuster branded drugs of the fluoroquinolones drug class. Aminoglycosides and macrolides together will be the fastest growing segment throughout the forecast period 2017-2025. Factors contributing to the growth of this segment are increasing incidences of antibiotics related drug resistance in bacterial conjunctivitis patients and technological advancement with effective clinical trials conducted analyzing the safety and efficacy of the antibiotic drug formulations at different concentrations resulting in immediate relief due to immediate onset of action.

In 2016, North America held the largest revenue share mainly due to factors such as rising prevalence of bacterial conjunctivitis, affordable reimbursement scenario and presence of developed research and healthcare institutions. Asia Pacific will be the fastest growing market throughout the forecast period 2017-2025, majorly due to factors such as high competition due to presence of existing and budding biopharmaceutical manufacturers involved in producing products for bacterial conjunctivitis treatment in this regions and supportive regulatory environment for bacterial conjunctivitis products and increasing disposable incomes.

Key Market Movements:

  • Rising prevalence of bacterial conjunctivitis
  • Rising public awareness regarding eye infections resulting in immediate treatment
  • Increasing air and water pollution and lack of self-hygiene
  • Supportive regulatory environment for bacterial conjunctivitis products

Based on drug class:

  • Fluoroquinolones
    • Ciprofloxacin
    • Ofloxacin
    • Levofloxacin
    • Moxifloxacin
    • Gatifloxacin
    • Besifloxacin
  • Aminoglycosides
    • Tobramycin
    • Gentamycin
  • Macrolides
    • Erythromycin
    • Azithromycin
  • Others (Phenicols, Glycolipopetides, Cyclic Polypeptides)

Be the first to comment

Leave a Reply

Your email address will not be published.


*